These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39031441)

  • 1. Loss of Chromosome Y in Neuroblastoma Is Associated With High-Risk Disease, 11q-Deletion, and Telomere Maintenance.
    Djos A; Svensson J; Gaarder J; Umapathy G; Nilsson S; Ek T; Vogt H; Georgantzi K; Öra I; Träger C; Kogner P; Martinsson T; Fransson S
    Genes Chromosomes Cancer; 2024 Jul; 63(7):e23260. PubMed ID: 39031441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation.
    Cetinkaya C; Martinsson T; Sandgren J; Träger C; Kogner P; Dumanski J; Díaz de Ståhl T; Hedborg F
    BMC Cancer; 2013 May; 13():231. PubMed ID: 23656755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene signatures associated with genomic aberrations predict prognosis in neuroblastoma.
    He X; Qin C; Zhao Y; Zou L; Zhao H; Cheng C
    Cancer Commun (Lond); 2020 Mar; 40(2-3):105-118. PubMed ID: 32237073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutional 11q14-q22 chromosome deletion syndrome in a child with neuroblastoma MYCN single copy.
    Passariello A; De Brasi D; Defferrari R; Genesio R; Tufano M; Mazzocco K; Capasso M; Migliorati R; Martinsson T; Siani P; Nitsch L; Tonini GP
    Eur J Med Genet; 2013 Nov; 56(11):626-34. PubMed ID: 24035971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of chromosome Y leads to down regulation of KDM5D and KDM6C epigenetic modifiers in clear cell renal cell carcinoma.
    Arseneault M; Monlong J; Vasudev NS; Laskar RS; Safisamghabadi M; Harnden P; Egevad L; Nourbehesht N; Panichnantakul P; Holcatova I; Brisuda A; Janout V; Kollarova H; Foretova L; Navratilova M; Mates D; Jinga V; Zaridze D; Mukeria A; Jandaghi P; Brennan P; Brazma A; Tost J; Scelo G; Banks RE; Lathrop M; Bourque G; Riazalhosseini Y
    Sci Rep; 2017 Mar; 7():44876. PubMed ID: 28332632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.
    Berbegall AP; Villamón E; Piqueras M; Tadeo I; Djos A; Ambros PF; Martinsson T; Ambros IM; Cañete A; Castel V; Navarro S; Noguera R
    Oncogene; 2016 Mar; 35(11):1423-32. PubMed ID: 26119945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion.
    Villamón E; Berbegall AP; Piqueras M; Tadeo I; Castel V; Djos A; Martinsson T; Navarro S; Noguera R
    PLoS One; 2013; 8(1):e53740. PubMed ID: 23341988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q.
    Boensch M; Oberthuer A; Fischer M; Skowron M; Oestreich J; Berthold F; Spitz R
    Diagn Mol Pathol; 2005 Sep; 14(3):177-82. PubMed ID: 16106200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low DLG2 gene expression, a link between 11q-deleted and MYCN-amplified neuroblastoma, causes forced cell cycle progression, and predicts poor patient survival.
    Keane S; Améen S; Lindlöf A; Ejeskär K
    Cell Commun Signal; 2020 Apr; 18(1):65. PubMed ID: 32312269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.
    Bogen D; Brunner C; Walder D; Ziegler A; Abbasi R; Ladenstein RL; Noguera R; Martinsson T; Amann G; Schilling FH; Ussowicz M; Benesch M; Ambros PF; Ambros IM
    Int J Cancer; 2016 Jul; 139(1):153-63. PubMed ID: 26910568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral immunosuppression profiles in 11q-deleted neuroblastomas provide new potential therapeutic targets.
    Coronado E; Yañez Y; Vidal E; Rubio L; Vera-Sempere F; Cañada-Martínez AJ; Panadero J; Cañete A; Ladenstein R; Castel V; Font de Mora J
    Mol Oncol; 2021 Feb; 15(2):364-380. PubMed ID: 33252831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification.
    Plantaz D; Vandesompele J; Van Roy N; Lastowska M; Bown N; Combaret V; Favrot MC; Delattre O; Michon J; Bénard J; Hartmann O; Nicholson JC; Ross FM; Brinkschmidt C; Laureys G; Caron H; Matthay KK; Feuerstein BG; Speleman F
    Int J Cancer; 2001 Mar; 91(5):680-6. PubMed ID: 11267980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
    Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
    Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma.
    Spitz R; Hero B; Simon T; Berthold F
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3368-73. PubMed ID: 16740759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Clin Cancer Res; 2003 Jan; 9(1):52-8. PubMed ID: 12538451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma.
    Lee E; Lee JW; Lee B; Park K; Shim J; Yoo KH; Koo HH; Sung KW; Park WY
    BMC Med Genomics; 2020 Nov; 13(1):171. PubMed ID: 33172452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
    Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
    Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How Do Telomere Abnormalities Regulate the Biology of Neuroblastoma?
    Akter J; Kamijo T
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative lengthening of telomeres--an enhanced chromosomal instability in aggressive non-MYCN amplified and telomere elongated neuroblastomas.
    Lundberg G; Sehic D; Länsberg JK; Øra I; Frigyesi A; Castel V; Navarro S; Piqueras M; Martinsson T; Noguera R; Gisselsson D
    Genes Chromosomes Cancer; 2011 Apr; 50(4):250-62. PubMed ID: 21319260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.